Create a management protocol for sepsis in the ICU
sepsis ICU management protocol diagnosis criteria Surviving Sepsis Campaign
Bailey and Love's Short Practice of Surgery 28th Edition
Page 80
sepsis fluid resuscitation vasopressors antibiotics source control
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 8273
sepsis empiric antibiotic therapy broad spectrum de-escalation blood cultures
| Term | Definition |
|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection (SOFA score ≥2 from baseline) |
| Septic Shock | Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation |
| qSOFA (screening) | ≥2 of: RR ≥22/min, altered mentation (GCS <15), SBP ≤100 mmHg |
| Parameter | Recommendation |
|---|---|
| Initial bolus | 30 mL/kg IV crystalloid within first 3 hours |
| Preferred fluid | Balanced crystalloids (e.g., Lactated Ringer's) or normal saline |
| Avoid | Hydroxyethyl starches (HES), gelatins |
| Reassessment tool | Focused cardiac ultrasound (bedside echo) if diagnosis unclear |
| Resuscitation target | Normalize lactate; target MAP ≥65 mmHg; avoid fluid overload |
Reassess volume status dynamically using passive leg raise, pulse pressure variation, or stroke volume variation to guide ongoing fluid therapy beyond the initial bolus.
| Clinical Context | Empiric Regimen |
|---|---|
| Community-acquired, no risk factors | Piperacillin-tazobactam OR a 3rd/4th generation cephalosporin ± metronidazole |
| Hospital-acquired / VAP / immunocompromised | Anti-pseudomonal beta-lactam (e.g., meropenem, cefepime) ± vancomycin or linezolid (MRSA coverage) |
| Suspected fungal (prolonged ICU stay, TPN, immunosuppression) | Add echinocandin (e.g., micafungin, caspofungin) |
| Intra-abdominal source | Piperacillin-tazobactam OR meropenem + metronidazole |
| Meningitis | Ceftriaxone + vancomycin + ampicillin (if Listeria risk) + dexamethasone |
| Agent | Role | Notes |
|---|---|---|
| Norepinephrine | First-line vasopressor | Preferred; start at 0.1–0.2 mcg/kg/min, titrate to MAP ≥65 mmHg |
| Vasopressin | Second-line add-on | 0.03–0.04 units/min; used to reduce norepinephrine dose (not to increase MAP further) |
| Epinephrine | Third-line / refractory shock | Add when norepinephrine + vasopressin insufficient |
| Dopamine | Avoid in most patients | Reserve for patients at highest risk of tachyarrhythmias or with relative bradycardia |
| Dobutamine | Cardiogenic component | Add if low cardiac output persists despite adequate preload and MAP |
Target MAP ≥65 mmHg — higher targets (e.g., 80–85 mmHg) do not improve outcomes in most patients and may increase arrhythmia risk.
| Indication | Regimen |
|---|---|
| Refractory septic shock (vasopressors not controlling MAP despite adequate fluids) | Hydrocortisone 200 mg/day IV (50 mg q6h or continuous infusion) |
| Duration | Until vasopressors are weaned; typically 5–7 days |
| Avoid routine use in sepsis without shock | — |
Fludrocortisone 50 mcg/day oral may be added alongside hydrocortisone per individual unit protocols.
| Intervention | Recommendation |
|---|---|
| DVT prophylaxis | LMWH (preferred) or UFH; mechanical if anticoagulation contraindicated |
| Stress ulcer prophylaxis | PPI or H₂ blocker for patients on mechanical ventilation or with coagulopathy |
| Nutrition | Initiate enteral nutrition within 24–48 hours of ICU admission; avoid parenteral nutrition in early phase if GI tract functional |
| Sedation | Minimize; use light sedation protocols (RASS target -1 to 0); prefer short-acting agents (propofol, dexmedetomidine) |
| Analgesia | Analgesia-first approach (analgosedation); fentanyl or morphine |
| Early mobility | Physiotherapy and passive/active mobilization as soon as hemodynamically stable |
| Head-of-bed elevation | 30–45° to reduce VAP risk |
| Parameter | Target |
|---|---|
| MAP | ≥65 mmHg |
| Lactate | <2 mmol/L; clearance ≥10% per 2 hours |
| SpO₂ | 92–96% |
| Urine output | ≥0.5 mL/kg/hour |
| Blood glucose | 140–180 mg/dL |
| Temperature | Treat fever (>38.5°C) or hypothermia (<36°C) |
| CVP / ScvO₂ | Use as trend markers, not absolute targets |